뒤로
Genocea Biosciences Inc (GNCAQ) 수입
GNCAQ 주가 차트
GNCAQ 수입
Genocea Biosciences Inc
$0
0%
$0
오늘 기준:Apr 01, 14:13:57 GMT-4
최신 수익 결과: Q1 '22
보고됨: 2022-05-05
역사적 수익
분기별
연간
EPS
수익
Earnings FAQ
GNCAQ의 최근 주당순이익(EPS)은 예상과 비교하여 어떤가요?
Genocea Biosciences Inc GNCAQ의 지난 분기 매출 실적은 어땠나요?
Genocea Biosciences Inc의 매출 추정치는 얼마인가요?
Genocea Biosciences Inc의 수익 품질 점수는 얼마인가요?
Genocea Biosciences Inc는 언제 수익을 보고하나요?
Genocea Biosciences Inc의 예상 수익은 얼마인가요?
Genocea Biosciences Inc은 수익 기대치를 충족했나요?
주요 통계
이전 종가
$0
시가
$0
일일 범위
$0 - $0
52주 범위
$0 - $0
거래량
4.5K
평균 거래량
0
배당수익률
--
EPS(TTM)
--
시가총액
$587.8000000000001
GNCAQ란 무엇인가요?
Genocea Biosciences, Inc. engages in the development and commercialization of cancer immunotherapies. The company is headquartered in Cambridge, Massachusetts and currently employs 74 full-time employees. The company went IPO on 2014-02-05. The firm is engaged in discovering and developing cancer immunotherapies using its proprietary ATLAS platform. The ATLAS platform can profile each patient's CD4+ and CD8+ T cell immune responses to every potential target or antigen identified by next-generation sequencing of that patient's tumor. ATLAS zeroes in on both antigens that activate anti-tumor T cell responses and inhibitory antigens, or Inhibigens, that drive pro-tumor immune responses. Its GEN-009 is an investigational neoantigen vaccine delivering adjuvanted synthetic long peptides from ATLAS-identified neoantigens. The firm has a license agreement with Harvard College (Harvard), granting the Company a sublicensable license to one patent family, to develop, make, use, market licensed products, and perform licensed services related to the ATLAS discovery platform.